Advancing personalized care in hemophilia A: ten years’ experience with an advanced category antihemophilic factor prepared using a plasma/albumin-free method

Advancing personalized care in hemophilia A: ten years’ experience with an advanced category antihemophilic factor prepared using a plasma/albumin-free method

Erik Berntorp,1 Gerald Spotts,2 Lisa Patrone,2 Bruce M Ewenstein2 1Malmö Centre for Thrombosis and Haemostasis, Lund University, Skåne University Hospital, Malmö, Sweden; 2Baxter Healthcare Corporation, Westlake Village, CA, USA Abstract: Detailed analysis of data from...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Berntorp E, Spotts G, Patrone L, Ewenstein BM
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2014
Materias:
Medicine (General)
R5-920
Acceso en línea:https://doaj.org/article/a55139c3d3774a4ca791671300ce97e3
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:a55139c3d3774a4ca791671300ce97e3
record_format dspace
spelling oai:doaj.org-article:a55139c3d3774a4ca791671300ce97e32021-12-02T02:41:20ZAdvancing personalized care in hemophilia A: ten years’ experience with an advanced category antihemophilic factor prepared using a plasma/albumin-free method1177-5475https://doaj.org/article/a55139c3d3774a4ca791671300ce97e32014-04-01T00:00:00Zhttp://www.dovepress.com/advancing-personalized-care-in-hemophilia-a-ten-yearsrsquo-experience--a16345https://doaj.org/toc/1177-5475 Erik Berntorp,1 Gerald Spotts,2 Lisa Patrone,2 Bruce M Ewenstein2 1Malmö Centre for Thrombosis and Haemostasis, Lund University, Skåne University Hospital, Malmö, Sweden; 2Baxter Healthcare Corporation, Westlake Village, CA, USA Abstract: Detailed analysis of data from studies of recombinant antihemophilic factor produced using a plasma/albumin-free method (rAHF-PFM) in previously treated patients showed a substantial level of interpatient variation in pharmacokinetics (PKs), factor VIII dosing, and annualized bleed rate (ABR), suggesting that individual patient characteristics contributed to outcome. For example, plasma half-life (t1/2), recovery, and clearance appeared to differ between patients aged <6 years and 10–65 years. Prophylaxis resulted in lower ABRs than episodic treatment in both age groups; better adherence to the prophylactic regimen resulted in a lower ABR in patients aged 10–65 years. The weekly frequency of dosing and adherence to dosing were both significantly and inversely related to the rate of bleeding (young children, P<0.0001 for both all bleeds and joint bleeds; older patients, P<0.0001 for all bleeds and P<0.05 for joint bleeds), as was adherence to dosing frequency (P<0.0001 for all comparisons). A postmarketing randomized study of prophylaxis demonstrated that a PK-guided dosing regimen, based on an individual patient’s rAHF-PFM PK (infusion interval, estimated t1/2, and recovery), was as effective as standard prophylaxis and that both prophylactic regimens were superior to episodic treatment with respect to ABR and quality of life measures. Thus, compared with standard prophylaxis, the PK-guided regimen achieved comparable efficacy with fewer weekly infusions. A two-compartment population PK model describes the PK data across the entire age range and forms the basis for future PK-guided therapy with rAHF-PFM. The model confirmed a shorter t1/2 and faster clearance of rAHF-PFM in children <6 years of age versus patients ≥10 years and predicted similar PK parameters with either a full or reduced blood sampling schedule, offering the potential for the use of PK-guided, individualized treatment in the routine clinical care setting. Keywords: rAHF-PFM, ADVATE, FVIII, prophylaxis, pharmacokinetics, individualizedBerntorp ESpotts GPatrone LEwenstein BMDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2014, Iss default, Pp 115-127 (2014)
institution DOAJ
collection DOAJ
language EN
topic Medicine (General)
R5-920
spellingShingle Medicine (General)
R5-920
Berntorp E
Spotts G
Patrone L
Ewenstein BM
Advancing personalized care in hemophilia A: ten years’ experience with an advanced category antihemophilic factor prepared using a plasma/albumin-free method
description Erik Berntorp,1 Gerald Spotts,2 Lisa Patrone,2 Bruce M Ewenstein2 1Malmö Centre for Thrombosis and Haemostasis, Lund University, Skåne University Hospital, Malmö, Sweden; 2Baxter Healthcare Corporation, Westlake Village, CA, USA Abstract: Detailed analysis of data from studies of recombinant antihemophilic factor produced using a plasma/albumin-free method (rAHF-PFM) in previously treated patients showed a substantial level of interpatient variation in pharmacokinetics (PKs), factor VIII dosing, and annualized bleed rate (ABR), suggesting that individual patient characteristics contributed to outcome. For example, plasma half-life (t1/2), recovery, and clearance appeared to differ between patients aged <6 years and 10–65 years. Prophylaxis resulted in lower ABRs than episodic treatment in both age groups; better adherence to the prophylactic regimen resulted in a lower ABR in patients aged 10–65 years. The weekly frequency of dosing and adherence to dosing were both significantly and inversely related to the rate of bleeding (young children, P<0.0001 for both all bleeds and joint bleeds; older patients, P<0.0001 for all bleeds and P<0.05 for joint bleeds), as was adherence to dosing frequency (P<0.0001 for all comparisons). A postmarketing randomized study of prophylaxis demonstrated that a PK-guided dosing regimen, based on an individual patient’s rAHF-PFM PK (infusion interval, estimated t1/2, and recovery), was as effective as standard prophylaxis and that both prophylactic regimens were superior to episodic treatment with respect to ABR and quality of life measures. Thus, compared with standard prophylaxis, the PK-guided regimen achieved comparable efficacy with fewer weekly infusions. A two-compartment population PK model describes the PK data across the entire age range and forms the basis for future PK-guided therapy with rAHF-PFM. The model confirmed a shorter t1/2 and faster clearance of rAHF-PFM in children <6 years of age versus patients ≥10 years and predicted similar PK parameters with either a full or reduced blood sampling schedule, offering the potential for the use of PK-guided, individualized treatment in the routine clinical care setting. Keywords: rAHF-PFM, ADVATE, FVIII, prophylaxis, pharmacokinetics, individualized
format article
author Berntorp E
Spotts G
Patrone L
Ewenstein BM
author_facet Berntorp E
Spotts G
Patrone L
Ewenstein BM
author_sort Berntorp E
title Advancing personalized care in hemophilia A: ten years’ experience with an advanced category antihemophilic factor prepared using a plasma/albumin-free method
title_short Advancing personalized care in hemophilia A: ten years’ experience with an advanced category antihemophilic factor prepared using a plasma/albumin-free method
title_full Advancing personalized care in hemophilia A: ten years’ experience with an advanced category antihemophilic factor prepared using a plasma/albumin-free method
title_fullStr Advancing personalized care in hemophilia A: ten years’ experience with an advanced category antihemophilic factor prepared using a plasma/albumin-free method
title_full_unstemmed Advancing personalized care in hemophilia A: ten years’ experience with an advanced category antihemophilic factor prepared using a plasma/albumin-free method
title_sort advancing personalized care in hemophilia a: ten years’ experience with an advanced category antihemophilic factor prepared using a plasma/albumin-free method
publisher Dove Medical Press
publishDate 2014
url https://doaj.org/article/a55139c3d3774a4ca791671300ce97e3
work_keys_str_mv AT berntorpe advancingpersonalizedcareinhemophiliaatenyearsrsquoexperiencewithanadvancedcategoryantihemophilicfactorpreparedusingaplasmaalbuminfreemethod
AT spottsg advancingpersonalizedcareinhemophiliaatenyearsrsquoexperiencewithanadvancedcategoryantihemophilicfactorpreparedusingaplasmaalbuminfreemethod
AT patronel advancingpersonalizedcareinhemophiliaatenyearsrsquoexperiencewithanadvancedcategoryantihemophilicfactorpreparedusingaplasmaalbuminfreemethod
AT ewensteinbm advancingpersonalizedcareinhemophiliaatenyearsrsquoexperiencewithanadvancedcategoryantihemophilicfactorpreparedusingaplasmaalbuminfreemethod
_version_ 1718402309837291520

Ejemplares similares